key: cord-0740400-javlffs2 authors: Peiffer-Smadja, Nathan; Rozencwajg, Sacha; Kherabi, Yousra; Yazdanpanah, Yazdan; Montravers, Philippe title: COVID-19 vaccines: a race against time date: 2021-03-24 journal: Anaesth Crit Care Pain Med DOI: 10.1016/j.accpm.2021.100848 sha: 1bfa6be04701c1776acb61430cab6b887f802434 doc_id: 740400 cord_uid: javlffs2 nan Less than one year after the declaration of COVID-19 as a pandemic disease by the Word Health Organization (WHO), the collaboration of the global scientific community has put on track no less than 308 vaccine candidates, among which 16 are currently in Phase III trials (1) results showing variable levels of cross-reaction depending on the viral strain (3). How much vaccines will be able to protect against infection due to these SARS-CoV-2 variants or to future emerging variants is still uncertain, and comparing estimates of their respective efficacy is a delicate challenge (4). Herein we briefly present the main vaccines in use around the world and discuss the challenges still ahead in 2021. The BioNTech-Pfizer vaccine is a lipid nanoparticle-formulated, nucleoside modified mRNA vaccine encoding full-length S protein. Its efficacy was first assessed in a double blind, randomised phase III trial across Argentina, Brazil, South Africa and USA, in which 43,548 participants were randomised to receive two 30 µg doses of BNT162b2 vaccine 21 days apart or placebo (5) . Protection occurred as early as the second week after the first vaccine administration, with an increase of protection against COVID-19 up to 95% after the second administration. The vaccine is reactogenic, but the side effects remained acceptable in all populations studied with a short-term safety profile characterised by mild to moderate pain at the injection site, fatigue and headache lasting less than 48 hours. No grade 4 adverse J o u r n a l P r e -p r o o f side effects were observed. Data for people over 75 were scarce in this trial and absent for children, pregnant women or immunocompromised patients. Efficacy was measured only in symptomatic patients, with no evidence of a potential effect against viral shedding. Data in a nationwide mass vaccination setting from Israel suggests that the effectiveness of the vaccine is consistent with that of the randomised trial (6) . This lipid nanoparticle encapsulated mRNA vaccine encodes pre fusion S protein. In a Phase III randomised, placebo-controlled trial conducted in 99 centres across the United States, in which persons at high risk for SARS-CoV-2 infection or its complications received two intramuscular doses or placebo 28 days apart, the vaccine showed 94.1% efficacy at preventing COVID-19 illness, including severe disease, at least 14 days after the second injection (7) . Hypersensitivity reactions were reported in 1.5% and 1.1% of participants respectively in the vaccine and placebo groups with three Bell's palsy in the vaccine group and 1 in the placebo group. The Oxford-AstraZeneca vaccine is based on a replication-deficient simian adenovirus (ChAdOx1) vector containing codon-optimised S protein. Efficacy data from a blinded, randomised, controlled trial across UK and Brazil, in which the control group received meningococcal vaccination (ACYW), showed a AZD1222 vaccine efficacy in the standard dose scheme (two standard doses, 28 days apart) of 62,1%, but a 90% efficacy in the low dose scheme (one low dose followed by a standard dose, 28 days apart) (8) . Immunocompromised volunteers were not included in the trial and few elderly participants (over 65) were represented, leading to a debate on the population for the EMA conditional marketing authorisation. At the time of writing, some European countries have temporarily suspended its use as a precautionary measure based on reports of rare blood clotting disorders in persons who had received this vaccine. However, WHO and EMA consider that the benefits of the AZD1222 vaccine outweigh its risks and thus recommends that vaccinations continue (9) . This single-shot recombinant adenovirus vaccine (Ad26) incorporates SARS-CoV-2 full stabilised S protein. First data regarding vaccine efficacy has been made public by the means of press release. A first interim analysis 28 days after a one-dose vaccination showed 66% efficacy at preventing moderate to severe COVID-19 with a 85% efficacy in preventing severe disease (10) . As the FDA did in February, EMA has granted an Emergency Use Authorization on March 11 for this vaccine, which is the last conditional approval to date for COVID-19 vaccines. Variant lineages of SARS-CoV-2 have been increasing around the world ( Table 1) . The N501Y mutation, which is present in the three main variants (UK, South African, Brazilian), modifies the receptor-binding domain of the S protein and may lead to 40 to 90% increased transmission (11,12). The 501Y.V2 and 501Y.V3 variants have another mutation, E484K, in the S protein that may confer a potential immune escape to antibodies (13 (17) Ad26.COV2.S: up to 85% efficacy (10) No data Data available for COVID-19 vaccines have mainly shown protection against symptomatic infections including severe COVID-19. However, preliminary data suggested that the Moderna vaccine could decrease asymptomatic infection by two-thirds as compared to the placebo, although the numbers were small and the design of the study not adapted for this analysis. Recent data with the AZD1222 vaccine also showed reduction in the duration of viral shedding and viral load among participants receiving it compared with placebo recipients (19) . This may suggest an impact on viral transmission but these data must be Finally, societal and global challenges must be met. There can be no global control of the pandemic without greater equity in the supply of vaccines, which are currently almost entirely purchased by the richest countries. In addition, vaccine hesitancy seems stronger than ever in the face of these rapidly developed vaccines in the context of a prolonged pandemic. It is now essential to create the conditions for a constructive dialogue between doctors, researchers and citizens in order to deliver reliable and constantly updated information on these vaccines. The "infodemic" of fake news can only be countered with transparent and honest medical information that succeeds in restoring faith in medicine. This challenge of medical communication aimed at the general public is probably one of the main challenges of modern science and medicine. COVID-19 vaccine tracker Vaccines are curbing COVID: Data from Israel show drop in infections SARS-CoV-2 variants and ending the COVID-19 pandemic. The Lancet Are some COVID vaccines better than others? Interpreting and comparing estimates of efficacy in trials of COVID-19 vaccines Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. The Lancet WHO statement on AstraZeneca COVID-19 vaccine safety signals single-shot-vaccine-in-fight-against-global-pandemic 11. Transmission of SARS-CoV-2 Lineage B.1.1.7 in England: Insights from linking epidemiological and genetic data | medRxiv Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma Neutralization of SARS-CoV-2 lineage B.1.1.7 pseudovirus by BNT162b2 vaccine-elicited human sera mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Pm 2:15. South Africa suspends use of AstraZeneca's COVID-19 vaccine after it fails to clearly stop virus variant Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study Efficacy of ChAdOx1 nCoV-19 (AZD1222) Vaccine Against SARS-CoV-2 Social Science Research Network